In the United States from August 1, 2021, to July 31, 2022, over 800 children died from COVID-19, while very few verified deaths have been linked to COVID-19 vaccines. The FDA is proposing significant changes to vaccine safety testing procedures in response to allegations that mRNA-based COVID-19 vaccines have led to at least 10 child fatalities. However, these claims are based on unproven assertions, and the FDA has yet to provide substantial evidence linking vaccine administration directly to the deaths of these children. The Vaccine Adverse Event Reporting System (VAERS) is a vital tool utilized to track adverse vaccine effects, but alone it cannot establish causation. Past studies show that unvaccinated children face a greater risk of heart complications due to COVID-19 than those who are vaccinated. Evidence indicates that myocarditis instances, though rare, can occur post-vaccination; however, patients have generally experienced fewer complications compared to myocarditis cases triggered by COVID-19 infection. Currently, the knowledge surrounding myocarditis and severe adverse reactions is limited due to the insufficient data from VAERS. In light of these concerns, the FDA suggests replacing antibody response studies for vaccine approval with an increased number of placebo-controlled trials. This recommendation aims to evaluate the safety of COVID-19 vaccines, along with widely-used influenza and pneumonia vaccines. Nonetheless, the practicality of such a proposal is questionable given the urgency and scale required for vaccine administration, particularly in light of ongoing mutations in viruses like COVID-19. Consequently, to accurately assess vaccine risks, comprehensive comparisons should be made between vaccine side effects and the detrimental effects of the diseases they aim to prevent.

The COVID-19 pandemic has had a profound impact on global health, prompting an urgent need for effective vaccines to control the spread of the virus. As vaccination efforts began worldwide, ensuring the safety of these vaccines became paramount to public health. The COVID-19 vaccine safety studies have employed various methodologies to assess both the short-term and long-term safety profiles of multiple vaccine candidates. These studies include randomized controlled trials, real-world effectiveness studies, and ongoing safety monitoring systems, which collectively contribute to understanding the risk-benefit ratio of vaccines. Clinical trials for COVID-19 vaccines, which began as early as 2020, have been extensive and rigorous. These trials typically involved tens of thousands of participants across diverse demographic groups. Researchers evaluated vaccine safety through the monitoring of adverse effects, categorizing them by severity and frequency. The initial data from these trials demonstrated that while some individuals experienced mild to moderate side effects such as fatigue, headache, and soreness at the injection site, serious adverse events were rare. These findings assured regulators about the vaccines' safety profiles, allowing for emergency use authorizations and subsequent distribution. In addition to the clinical trials, safety studies have continued post-market through systems such as the Vaccine Adverse Event Reporting System (VAERS) in the United States. This system collects reports of adverse events following vaccination, providing valuable insights into rare side effects that may not have been evident during clinical trials. Moreover, ongoing observational studies have contributed to the accumulation of real-world data, which supports the vaccines' overall safety and efficacy. Findings from these studies confirm that the benefits of vaccination in preventing COVID-19, including severe illness and hospitalization, far outweigh the risks associated with potential side effects. As of December 2025, ongoing safety surveillance remains critical, particularly as new variants of the virus emerge and public health recommendations continue to evolve. Regulatory agencies such as the Centers for Disease Control and Prevention (CDC) and the European Medicines Agency (EMA) maintain vigilance through continuous safety assessments. Emerging data continues to inform the understanding of vaccine safety, ensuring that the public receives updated information. The commitment to transparency in reporting vaccine safety data has been essential in building public trust and encouraging vaccine uptake, a vital factor in controlling the COVID-19 pandemic.